Cargando…
Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer
This randomised multicentre trial was conducted to establish the optimal duration of palliative chemotherapy in advanced non-small-cell lung cancer (NSCLC). We compared a policy of three vs six courses of new-generation platinum-based combination chemotherapy with regard to effects on quality of lif...
Autores principales: | von Plessen, C, Bergman, B, Andresen, O, Bremnes, R M, Sundstrom, S, Gilleryd, M, Stephens, R, Vilsvik, J, Aasebo, U, Sorenson, S |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360695/ https://www.ncbi.nlm.nih.gov/pubmed/17047644 http://dx.doi.org/10.1038/sj.bjc.6603383 |
Ejemplares similares
-
Concurrent palliative chemoradiation leads to survival and quality of life benefits in poor prognosis stage III non-small-cell lung cancer: a randomised trial by the Norwegian Lung Cancer Study Group
por: Strøm, H H, et al.
Publicado: (2013) -
Poor Prognosis Patients with Inoperable Locally Advanced NSCLC and Large Tumors Benefit from Palliative Chemoradiotherapy: A Subset Analysis from a Randomized Clinical Phase III Trial
por: Strøm, Hans H., et al.
Publicado: (2014) -
Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group
por: Fløtten, Ø, et al.
Publicado: (2012) -
Beyond the East/West Dichotomy—The Course Yoga: Theory and Practice Conveys the Benefits of an Ayurvedic Lens for Global Health
por: Klatt, Maryanna, et al.
Publicado: (2019) -
Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity
por: Helbekkmo, N, et al.
Publicado: (2007)